Interleukin-10: From Immunosuppressant to a Game-Changer in Cancer Immunotherapy

Discovered in the 1990s, Interleukin-10 (IL-10) has become a crucial player in the realm of immunology, with its influence reaching far and wide across various immune processes. This article aims to delve into the intricate functions of IL-10 in immunology and its intriguing impact on tumor biology, unraveling the complexities and controversies surrounding its role.

Understanding IL-10's Structure and Regulation

IL-10, a protein consisting of 178 amino acids, takes the form of a V-shaped homodimer. Widely produced by cells like monocytes, macrophages, dendritic cells, B cells, and different T cell subsets, IL-10's expression is finely regulated at both transcriptional and post-transcriptional levels. Complex interactions involving cytokines like IL-6 and IL-27, coupled with STAT1 and STAT3 activations, contribute to this precise control. Epigenetic factors, such as histone modification, add another layer of regulation, showcasing the intricate orchestration of IL-10 in cellular responses.

Decoding the IL-10 Signaling Pathway

The IL-10 receptor, composed of IL-10R1 and IL-10R2 subunits, triggers Janus kinase 1 (Jak1) and Tyrosine kinase 2 (Tyk2) upon IL-10 binding. This sets off a signaling cascade involving STAT1, STAT3, and STAT5. The duration of STAT3 activation proves crucial for IL-10's impact, with implications for specific cell responses. While IL-10R lacks STAT1 sites, the presence of IFN-γ aids in its interaction with IFN-γR or another receptor, potentially favoring STAT1 over STAT3. Further research is needed to fully understand this process.

Unraveling the Immunobiology of IL-10

IL-10's influence on immune cells manifests in diverse and context-dependent ways. It stimulates the proliferation and cytolytic activity of CD8+ T cells under specific conditions, yet induces T cell anergy under different circumstances. CD4+ T cells, NK cells, B cells, and macrophages exhibit varied responses to IL-10, emphasizing the nuanced role of this cytokine in immune regulation.

In cytotoxic T lymphocytes (CTLs), IL-10, when combined with IL-4 and/or IL-2, stimulates proliferation and enhances cytolytic activity. Interestingly, the co-stimulatory effects of IL-10 on CD8+ T cells are dependent on factors like IL-2 and IL-4. In CD4+ T cells, IL-10 can induce inactivation under specific conditions, characterized by the inhibition of pro-inflammatory cytokine production. However, various subpopulations of CD4+ helper T cells, including Th1, Th2, and Th17, have been identified as significant sources of IL-10, suggesting its role in self-regulation during infection.

NK cells display a complex relationship with IL-10, showing both suppression and stimulation. In vitro, IL-10 suppresses NK expression of pro-inflammatory cytokines, while in vivo, it enhances NK cytolytic activity synergistically with IL-18. This emphasizes the need to reevaluate the immunosuppressive nature of IL-10 on a case-by-case basis within the tissue microenvironment.

B cells consistently demonstrate stimulatory effects in response to IL-10. It promotes B cell survival, proliferation, and differentiation into plasma cells. The stimulatory effects on B cells contrast with conflicting data observed in other immune cell types. Macrophages exhibit diverse responses to IL-10, including the suppression of MHC class II expression, contributing to the inhibition of Th1 cells. However, certain in vivo studies have shown that macrophages gain migratory capacity in the absence of IL-10, suggesting a complex interplay.

?

?IL-10 in Cancer Biology

The role of IL-10 in tumor pathogenesis and development remains controversial, reflecting the dual nature of this cytokine. Some studies suggest that IL-10 positively contributes to tumor growth, while others indicate its role in eradication and suppression of angiogenesis and metastasis, crucial for long-term patient survival.

In the potential role of IL-10 in tumor promotion, its widely accepted immunosuppressive nature positions it as a facilitator of tumor immune escape. Multiple studies have reported a positive correlation between IL-10 levels and poor prognosis for various cancer types. Tumor cells themselves produce IL-10, using its expression as an escape mechanism from immune surveillance. This involves reducing or inhibiting antigen presentation, creating an immunosuppressive environment that facilitates tumor escape.

The complexity arises from the in vivo relationship between inflammation and tumor progression. Monocytes/macrophages, contributors to tumor progression, release factors promoting angiogenesis and metastasis. Some activated macrophages, particularly M2-activated macrophages prevalent in the tumor microenvironment, release significant amounts of IL-10. This prompts a question of correlation versus causation between IL-10 and tumor growth.

Transforming growth factor-beta (TGF-β), secreted by macrophages, has been implicated in tumor progression. IL-10 levels are concomitant with TGF-β secretion in T regulatory cells and macrophages. Studies have shown that TGF-β, in combination with IL-6, results in IL-10 secretion by Th-17 cells, further complicating the determination of the causal relationship between IL-10 production and cancer growth. Studies have reported IL-10 secretion by tumor cells themselves, suggesting an autocrine signaling mechanism that contributes to tumor progression.

In the potential role of IL-10 in tumor inhibition, evidence suggests potent anti-tumor effects. Murine tumor models engineered to express murine IL-10 showed rapid rejection that increased with IL-10 secretion. This aligns with the finding that IL-10 plays a crucial role in proper CD8 T cell memory development and function.

Intravenous injection of pegylated IL-10 resulted in the rejection of implanted tumors, accompanied by increased expression of cytotoxic markers. Interestingly, these effects were not observed in IL-10 receptor knockout mice, indicating the specificity of IL-10 action. Another study showed that tumor cells engineered to express IL-10 were rejected, and established tumors displayed reduced growth rates upon injection of IL-10, with inhibition of metastasis in an immune-dependent manner. The decreased expression of factors related to angiogenesis and metastasis suggested mechanisms affected by IL-10.

A proposed mechanism for IL-10's anti-tumor activity involves its stimulation of NK cells. IL-10 has been shown to directly stimulate NK cells and indirectly enhance NK activity in vivo. Tumor-associated macrophages (TAMs) have been shown to deactivate NK cells, and IL-10 inhibits this deactivation. Tumor-resident NK cells have been shown to increase factors favoring cytotoxicity in response to IL-10. This proposed tumoricidal activity assists CTL stimulation by making more tumor-associated antigens available to activate the adaptive response.

Decreased expression of MHC/HLA molecules activates NK cells and increases cytotoxic function. IL-10 reduces the expression of MHC class II molecules in antigen-presenting cells and MHC class I on tumor cells. This decreased MHC expression may facilitate NK-mediated tumor rejection and inhibit metastasis. Studies have linked IL-10-induced repression of MHC expression to enhanced NK-mediated tumor rejection and/or inhibition of metastasis.

IL-10's inhibitory effect on angiogenesis supports its anti-tumor potential. Angiogenesis, crucial for tumor growth, is inhibited by IL-10 through downregulation of VEGF production. This anti-angiogenic property is further confirmed in studies showing that IL-10 overexpression in tumor cells results in reduced microvessel density and suppressed tumor growth.

Furthermore, IL-10's inhibitory effect on matrix metalloproteinases (MMPs) adds another layer to its anti-tumor capabilities. MMPs play a pivotal role in tumor invasion and metastasis by degrading the extracellular matrix. Studies have demonstrated that IL-10 suppresses the expression of MMP-2 and MMP-9 in various cancer types, suggesting its potential to hinder metastatic processes.

Using IL-10 in Cancer Immunotherapy

In recent years, IL-10 has emerged as a promising tool in cancer immunotherapy. Its impact on crucial components, such as activated and exhausted T-cells, along with its influence on macrophages and dendritic cells (DCs), highlights its potential to enhance the immune response against tumors.

Activated T-cells, essential components of the immune system, face challenges when overstimulated, particularly by DCs. IL-10 acts by downregulating the stimulatory capacity of DCs, creating a balance that prevents excessive T-cell activation and reduces IFN-γ production. This ultimately leads to decreased T-cell apoptosis, maintaining the viability of newly primed tumor-specific T-cells resulting from treatments like oncolytic virus therapy or vaccines.

Exhausted T-cells, commonly found infiltrating tumors, present defective mitochondrial metabolism and high levels of inhibitory receptors. IL-10 promotes oxidative phosphorylation within the mitochondria, restoring ATP production and rescuing T-cell function. Simultaneously, it downregulates inhibitory receptors, ensuring a comprehensive restoration of the function of tumor-specific T-cells residing in the tumor microenvironment (TME) prior to treatment.

Macrophages are also affected by IL-10 via downregulation of MHC-I and II, as well as the production of inflammatory cytokines. In the context of oncolytic virotherapy, this modulation can be advantageous. It allows the virus to linger longer within the system, contributing to increased tumor cell death.

Dendritic cells, integral to the orchestration of immune responses, are also affected by IL-10. Acting as a safeguard against excessive activation, IL-10 downregulates the immunostimulatory function of DCs. This measured modulation becomes crucial in the context of newly activated tumor-specific T-cells, ensuring their protection against premature demise due to overstimulation.

In summary, IL-10's potential in cancer immunotherapy lies in its effect on activated and exhausted T-cells, macrophages, and dendritic cells. The potential combination of IL-10 with oncolytic virotherapy and therapeutic cancer vaccines brings optimism to the ongoing battle against cancer.

Conclusion

The intricate role of Interleukin-10 in immunology and tumor pathogenesis reflects its multifaceted nature. While IL-10 is recognized as a potent immunosuppressive cytokine, the context-dependent and cell-specific effects challenge simplistic categorizations. The duality of IL-10's influence on cancer, with both tumor-promoting and tumor-inhibitory aspects, adds to the complexity. The delicate balance between immunosuppression and anti-tumor immunity suggests that harnessing IL-10's potential for therapeutic purposes requires a nuanced understanding of its mechanisms.

Future directions in IL-10 research should focus on unraveling the intricate signaling pathways and crosstalk with other cytokines, dissecting the cell-specific responses, and delineating the molecular basis of its contrasting roles in tumor biology. This comprehensive exploration lays the groundwork for further investigations, emphasizing the need for a holistic understanding of IL-10's role in health and disease. As the scientific community delves deeper into the complexities of IL-10, it becomes evident that deciphering its enigmatic nature holds the key to unlocking novel therapeutic strategies in the realms of immunology and cancer biology.